Dare Bioscience Inc (DARE)

$2.55 -0.02 (-0.78%)
Market Cap 22.75M
Revenue (ttm) 10,000.00
Net Income (ttm) -4.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -40,500.00%
Debt to Equity Ratio 0.00
Volume 225,500
Avg Vol 1,841,668
Day's Range N/A - N/A
Shares Out 8.85M
Stochastic %K 28%
Beta 1.14
Analysts Strong Sell
Price Target $13.00

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 926 7655
Address:
3655 Nobel Drive, Suite 260, San Diego, United States
petertradebull
petertradebull Jul. 28 at 11:43 PM
$DARE Sabrina must be replaced 🚀🚀🚀
0 · Reply
UniversalTrading
UniversalTrading Jul. 28 at 8:35 PM
$DARE P O S
0 · Reply
achalm15
achalm15 Jul. 28 at 6:02 PM
$DARE c’mon let’s have a surprise buyout.
0 · Reply
petertradebull
petertradebull Jul. 28 at 11:39 AM
$DARE when $30? Sabrina still here? 🚀🚀🚀
0 · Reply
1403tage
1403tage Jul. 27 at 8:15 PM
$DARE short 12,73% lets hope they lose their bets
0 · Reply
JCMont
JCMont Jul. 27 at 9:12 AM
$DARE On July 24, 2025, Daré Bioscience, Inc. (“Daré,” “we,” “us,” “our” or the “Company”) received a letter from the Nasdaq Office of General Counsel confirming that the Company demonstrated compliance with the stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”), and that the Company is therefore in compliance with the Nasdaq Capital Market’s continued listing requirements.
0 · Reply
UniversalTrading
UniversalTrading Jul. 26 at 4:27 PM
$DARE Those who know .. know. DD is crsytal here .. Will replace Sabrina .. has too .. no question. Ignore the Noise and fuckery .. simply the MM's holding it down. When this decides to climb it will literally rocket. The ASC Scale to Ratio Chart on $ GAME looks insane now. Literally bubbling and primed to Run hard. Buy all you can at this SP level .. this SP level will be long gone soon. GLTA.
1 · Reply
Green_Party
Green_Party Jul. 25 at 4:56 PM
$DARE Good news is that DARE reached equity and is currently compliant with NASDAQ so no threat of delisting while they maintain. Bad news, as expected, is that they sold $16 million worth of shares, hence the value crash after the announcement. Probably added 3-5 million shares which is pretty massive dilution. They had to do it, but it still sucks. Probably some sildenafil announcements in Q3 and Q4, though, so some good potential for more catalysts.
2 · Reply
OhLawdy
OhLawdy Jul. 25 at 4:16 PM
$DARE $2.5 Million equity requirement met. Enjoy your weekends!
0 · Reply
joeycash_
joeycash_ Jul. 25 at 12:07 PM
$DARE
0 · Reply
Latest News on DARE
UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 21, 2025, 1:47 PM EDT - 7 days ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Jul 14, 2025, 1:09 PM EDT - 14 days ago

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Jul 14, 2025, 8:00 AM EDT - 14 days ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jul 11, 2025, 8:00 AM EDT - 17 days ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:00 PM EDT - 6 weeks ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

May 13, 2025, 11:13 PM EDT - 2 months ago

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025, 4:01 PM EDT - 2 months ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:14 PM EDT - 4 months ago

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 31, 2025, 4:01 PM EDT - 4 months ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Mar 24, 2025, 8:00 AM EDT - 4 months ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Feb 6, 2025, 8:00 AM EST - 6 months ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 7 months ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:03 PM EST - 9 months ago

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 14, 2024, 4:01 PM EST - 9 months ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 9 months ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 23, 2024, 12:30 PM EDT - 9 months ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Oct 21, 2024, 8:05 AM EDT - 10 months ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 8:40 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Daré Bioscience Announces Reverse Stock Split

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Reverse Stock Split

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

May 14, 2024, 6:30 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 14, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

May 2, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:47 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 21, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

This overlooked corner of women's health could be a $350 billion market opportunity

Mar 15, 2024, 2:33 PM EDT - 1 year ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 31, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 26, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 17, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Jan 4, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 26, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 20, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Dec 13, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:56 PM EST - 1 year ago

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 9, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Daré Bioscience to Participate in Three November Conferences

Nov 6, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in Three November Conferences

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

Aug 9, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

Jul 11, 2023, 5:30 PM EDT - 2 years ago

Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

Jun 21, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference

petertradebull
petertradebull Jul. 28 at 11:43 PM
$DARE Sabrina must be replaced 🚀🚀🚀
0 · Reply
UniversalTrading
UniversalTrading Jul. 28 at 8:35 PM
$DARE P O S
0 · Reply
achalm15
achalm15 Jul. 28 at 6:02 PM
$DARE c’mon let’s have a surprise buyout.
0 · Reply
petertradebull
petertradebull Jul. 28 at 11:39 AM
$DARE when $30? Sabrina still here? 🚀🚀🚀
0 · Reply
1403tage
1403tage Jul. 27 at 8:15 PM
$DARE short 12,73% lets hope they lose their bets
0 · Reply
JCMont
JCMont Jul. 27 at 9:12 AM
$DARE On July 24, 2025, Daré Bioscience, Inc. (“Daré,” “we,” “us,” “our” or the “Company”) received a letter from the Nasdaq Office of General Counsel confirming that the Company demonstrated compliance with the stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”), and that the Company is therefore in compliance with the Nasdaq Capital Market’s continued listing requirements.
0 · Reply
UniversalTrading
UniversalTrading Jul. 26 at 4:27 PM
$DARE Those who know .. know. DD is crsytal here .. Will replace Sabrina .. has too .. no question. Ignore the Noise and fuckery .. simply the MM's holding it down. When this decides to climb it will literally rocket. The ASC Scale to Ratio Chart on $ GAME looks insane now. Literally bubbling and primed to Run hard. Buy all you can at this SP level .. this SP level will be long gone soon. GLTA.
1 · Reply
Green_Party
Green_Party Jul. 25 at 4:56 PM
$DARE Good news is that DARE reached equity and is currently compliant with NASDAQ so no threat of delisting while they maintain. Bad news, as expected, is that they sold $16 million worth of shares, hence the value crash after the announcement. Probably added 3-5 million shares which is pretty massive dilution. They had to do it, but it still sucks. Probably some sildenafil announcements in Q3 and Q4, though, so some good potential for more catalysts.
2 · Reply
OhLawdy
OhLawdy Jul. 25 at 4:16 PM
$DARE $2.5 Million equity requirement met. Enjoy your weekends!
0 · Reply
joeycash_
joeycash_ Jul. 25 at 12:07 PM
$DARE
0 · Reply
petertradebull
petertradebull Jul. 25 at 11:38 AM
$DARE $30 soon? Sabrina must be replaced 🚀🚀🚀
0 · Reply
HMIC
HMIC Jul. 25 at 11:00 AM
$DARE IYKYK
0 · Reply
UniversalTrading
UniversalTrading Jul. 24 at 4:21 PM
$DARE Crikey .. what an absolute POS!!
0 · Reply
Rampageusa
Rampageusa Jul. 24 at 2:02 PM
$DARE $NMHI,$FFAI dead cat bounce ,
0 · Reply
monstamike
monstamike Jul. 24 at 1:46 PM
$DARE looking good to grind up
0 · Reply
petertradebull
petertradebull Jul. 24 at 11:53 AM
$DARE when $30? 🚀🚀🚀
0 · Reply
Blondestocks
Blondestocks Jul. 24 at 12:20 AM
$DARE waiting for tomorrow 💕❤️
0 · Reply
RMAW
RMAW Jul. 23 at 11:40 PM
$DARE THIS IS A BUY OUT WAITING TO HAPPEN!!! 🤑🤑🤑
1 · Reply
petertradebull
petertradebull Jul. 23 at 10:38 PM
$DARE Sabrina still here I guess. 🚀🚀🚀
0 · Reply
GolfPro999
GolfPro999 Jul. 23 at 9:44 PM
$DARE over or under $3.50 end of day tomorrow?
0 · Reply
F_The_short
F_The_short Jul. 23 at 8:47 PM
$DARE Loaded and This is for the short 😂😂😂😂😂🚀🚀🚀🚀🚀
0 · Reply
Billionaire_4480
Billionaire_4480 Jul. 23 at 3:47 PM
$DARE added
0 · Reply